Innate immune tolerance and the role of kupffer cells in differential responses to interferon therapy among patients with HCV genotype 1 infection

Gastroenterology

Volumn 144, Issue 2, 2013, Pages

  Lau, Daryl T Y ^a   Negash, Amina ^b   Chen, Jie ^a   Crochet, Nanette ^b   Sinha, Mala ^c,d   Zhang, Yuhong ^a   Guedj, Jeremie ^e   Holder, Sharon ^a   Saito, Takeshi ^b   Lemon, Stanley M ^f   Luxon, Bruce A ^c,d   Perelson, Alan S ^e   Gale Jr , Michael ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c University of Texas Medical Branch School of Medicine   (United States)

^d UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^e LOS ALAMOS NATIONAL LABORATORY   (United States)

^f UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Drug; Microarray analysis; PBMC; Therapeutic efficacy

Indexed keywords

ALPHA2A INTERFERON; BETA INTERFERON; MESSENGER RNA; RIBAVIRIN; VIRUS RNA; ALPHA INTERFERON; INTERFERON REGULATORY FACTOR; RECOMBINANT PROTEIN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CELL FUNCTION; CLINICAL ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE; GENE CLUSTER; GENE EXPRESSION; HEALTH CARE QUALITY; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS SUBTYPE 2A; HEPATOMA CELL; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; INNATE IMMUNITY; INTERFERON STIMULATED GENE; KUPFFER CELL; LIPID METABOLISM; LIVER BIOPSY; LIVER CELL; MACROPHAGE; MALE; MIDDLE AGED; NONHUMAN; OUTCOME ASSESSMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPEAT PROCEDURE; SINGLE DRUG DOSE; SYSTEMS BIOLOGY; TISSUE DISTRIBUTION; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD; YOUNG ADULT; BIOPSY; BIOSYNTHESIS; CELL CULTURE; COMPARATIVE STUDY; DRUG EFFECT; FOLLOW UP; GENE EXPRESSION REGULATION; GENETICS; GENOTYPE; HEPATITIS C VIRUS; IMMUNOLOGY; LIVER; METABOLISM; PATHOLOGY; THEORETICAL MODEL; VIROLOGY;

ADULT; BIOPSY; CELLS, CULTURED; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HEPATOCYTES; HUMANS; IMMUNE TOLERANCE; IMMUNITY, INNATE; INTERFERON REGULATORY FACTORS; INTERFERON-ALPHA; KUPFFER CELLS; LIVER; MALE; MIDDLE AGED; MODELS, THEORETICAL; RECOMBINANT PROTEINS; RNA, VIRAL; VIRAL LOAD; YOUNG ADULT;

EID: 84881522909     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2012.10.044     Document Type: Article

References (28)

1. Ghany MG, Nelson DR, Strader DB, et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011;54:1433-1444.
2. Schoggins JW, Wilson SJ, Panis M, et al. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 2011;472:481-485.
3. Gale M Jr, Foy EM. Evasion of intracellular host defence by hepatitis C virus. Nature 2005;436:939-945.
4. Edlich B, Ahlenstiel G, Zabaleta Azpiroz AZ, et al. Early changes in interferon signaling define natural killer cell response and refractoriness to interferon-based therapy of hepatitis C patients. Hepatology 2012;55:39-48.
5. Sumpter R Jr, Wang C, Foy E, et al. Viral evolution and interferon resistance of hepatitis C virus RNA replication in a cell culture model. J Virol 2004;78:11591-11604.
6. Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998;282:103-107.
7. Lam NP, Neumann AU, Gretch DR, et al. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 1997;26:226-231.
8. Lau DT, Fish PM, Sinha M, et al. Interferon regulatory factor-3 activation, hepatic interferon-stimulated gene expression, and immune cell infiltration in hepatitis C virus patients. Hepatology 2008;47:799-809.
9. Loo YM, Owen DM, Li K, et al. Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection. Proc Natl Acad Sci U S A 2006;103:6001-6006.
10. Fensterl V, Sen GC. Interferons and viral infections. Biofactors 2009;35:14-20.
11. Thomas E, Gonzalez VD, Li Q, et al. HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons. Gastroenterology 2012;142: 978-988.
12. Wang C, Pflugheber J, Sumpter R Jr, et al. Alpha interferon induces distinct translational control programs to suppress hepatitis C virus RNA replication. J Virol 2003;77:3898-3912.
13. Sarasin-Filipowicz M, Oakeley EJ, Duong FH, et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A 2008;105:7034-7039.
14. Stienstra R, Saudale F, Duval C, et al. Kupffer cells promote hepatic steatosis via interleukin-1beta-dependent suppression of peroxisome proliferator-activated receptor alpha activity. Hepatology 2010;51:511-522.
15. Pflugheber J, Fredericksen B, Sumpter R Jr, et al. Regulation of PKR and IRF-1 during hepatitis C virus RNA replication. Proc Natl Acad Sci U S A 2002;99:4650-4655.
16. Sarkar SN, Sen GC. Novel functions of proteins encoded by viral stress-inducible genes. Pharmacol Ther 2004;103:245-259.
17. Sumpter R Jr, Loo YM, Foy E, et al. Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I. J Virol 2005;79:2689-2699.
18. Takahashi K, Asabe S, Wieland S, et al. Plasmacytoid dendritic cells sense hepatitis C virus-infected cells, produce interferon, and inhibit infection. Proc Natl Acad Sci U S A 2010;107: 7431-7436.
19. Chen L, Borozan I, Feld J, et al. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 2005;128:1437-1444.
20. Feld JJ, Nanda S, Huang Y, et al. Hepatic gene expression during treatment with peginterferon and ribavirin: identifying molecular pathways for treatment response. Hepatology 2007;46:1548-1563.
21. Dill MT, Duong FH, Vogt JE, et al. Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology 2011; 140:1021-1031.
22. Chen L, Borozan I, Sun J, et al. Cell-type specific gene expression signature in liver underlies response to interferon therapy in chronic hepatitis C infection. Gastroenterology 2010;138:1123-1133.
23. Loo YM, Gale M Jr. Viral regulation and evasion of the host response. Curr Top Microbiol Immunol 2007;316:295-313.
24. Loo YM, Owen DM, Li K, et al. Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection. Proc Natl Acad Sci U S A 2006;103:6001-6006.
25. Erickson AK, Seiwert S, Gale M Jr. Antiviral potency analysis and functional comparison of consensus interferon, interferon-alpha2a and pegylated interferon-alpha2b against hepatitis C virus infection. Antivir Ther 2008;13:851-862.
26. Wang C, Pflugheber J, Sumpter R Jr, et al. Alpha interferon induces distinct translational control programs to suppress hepatitis C virus RNA replication. J Virol 2003;77:3898-3912.
27. Lau DT, Fish PM, Sinha M, et al. Interferon regulatory factor-3 activation, hepatic interferon-stimulated gene expression, and immune cell infiltration in hepatitis C virus patients. Hepatology 2008;47:799-809.
28. Li Q, Duan L, Estes JD, et al. Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells. Nature 2005;434:1148-1152.